OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.720
-0.010 (-0.58%)
Aug 5, 2025, 4:00 PM - Market closed
Ligand Pharmaceuticals Stock Forecast
OSTX's stock price has decreased by -57% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $18, which forecasts a 946.51% increase in the stock price over the next year. The lowest target is $15 and the highest is $20.
Price Target: $18.00 (+946.51%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +1,062.79% | Jul 14, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +1,062.79% | Jul 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +1,062.79% | Jun 30, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +1,062.79% | Jun 24, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +1,062.79% | Jun 10, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
19.72M
EPS This Year
0.69
from -0.88
EPS Next Year
-0.04
from 0.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 33.9M | 58.2M |
| Avg | n/a | 19.7M | 35.6M |
| Low | n/a | n/a | 8.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 195.1% |
| Avg | - | - | 80.6% |
| Low | - | - | -57.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.70 | 0.47 | 0.07 |
| Avg | 0.69 | -0.04 | -0.08 |
| Low | -0.30 | -0.33 | -0.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | -31.5% | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.